AVEO Pharma (AVEO) Receives a Buy from SVB Securities

In a report issued on May 5, Andrew Berens from SVB Securities assigned a Buy rating to AVEO Pharma (AVEOResearch Report), with a price target of $15.00. The company’s shares closed last Friday at $4.31.

According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of -13.5% and a 36.1% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.

Currently, the analyst consensus on AVEO Pharma is a Strong Buy with an average price target of $15.75, representing a 246.2% upside. In a report issued on May 5, Robert W. Baird also maintained a Buy rating on the stock with a $17.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $7.59 and a one-year low of $3.06. Currently, AVEO Pharma has an average volume of 285K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Read More on AVEO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed